BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Saab S, Gordon SC, Park H, Sulkowski M, Ahmed A, Younossi Z. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther 2014;40:657-75. [PMID: 25065960 DOI: 10.1111/apt.12871] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Nuño Solinís R, Arratibel Ugarte P, Rojo A, Sanchez Gonzalez Y. Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence. Infect Dis Ther 2016;5:491-508. [PMID: 27783223 DOI: 10.1007/s40121-016-0134-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
2 Younossi Z, Henry L. The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C. Dig Liver Dis. 2014;46 Suppl 5:S186-S196. [PMID: 25458773 DOI: 10.1016/j.dld.2014.09.025] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 6.4] [Reference Citation Analysis]
3 Marco A, Domínguez-Hernández R, Casado MA. Cost-effectiveness analysis of chronic hepatitis C treatment in the prison population in Spain. Rev Esp Sanid Penit 2020;22:66-74. [PMID: 32697276 DOI: 10.18176/resp.00012] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Alavian SM, Nikfar S, Kebriaeezadeh A, Lotfi F, Sanati E, Rezaei Hemami M, Keshavarz K. A Cost-Utility Analysis of Different Antiviral Medicine Regimens in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. Iran Red Crescent Med J 2016;18:e37094. [PMID: 28203449 DOI: 10.5812/ircmj.37094] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
5 Saab S, Virabhak S, Parisé H, Johnson S, Wang A, Misurski D, Gonzalez YS, Juday T. Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States. Adv Ther 2016;33:1316-30. [PMID: 27342742 DOI: 10.1007/s12325-016-0362-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
6 Greenaway C, Makarenko I, Chakra CNA, Alabdulkarim B, Christensen R, Palayew A, Tran A, Staub L, Pareek M, Meerpohl JJ, Noori T, Veldhuijzen I, Pottie K, Castelli F, Morton RL. The Effectiveness and Cost-Effectiveness of Hepatitis C Screening for Migrants in the EU/EEA: A Systematic Review. Int J Environ Res Public Health 2018;15:E2013. [PMID: 30223539 DOI: 10.3390/ijerph15092013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
7 Pandya P, Rzouq F, Oni O. Sustained virologic response and other potential genotype-specific roles of statins among patients with hepatitis C-related chronic liver diseases. Clin Res Hepatol Gastroenterol. 2015;39:555-565. [PMID: 25835493 DOI: 10.1016/j.clinre.2015.02.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
8 Luhnen M, Waffenschmidt S, Gerber-Grote A, Hanke G. Health Economic Evaluations of Sofosbuvir for Treatment of Chronic Hepatitis C: a Systematic Review. Appl Health Econ Health Policy. 2016;14:527-543. [PMID: 27329481 DOI: 10.1007/s40258-016-0253-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
9 Mattingly TJ 2nd, Slejko JF, Onukwugha E, Perfetto EM, Kottilil S, Mullins CD. Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness Analysis. Pharmacoeconomics 2020;38:233-42. [PMID: 31788751 DOI: 10.1007/s40273-019-00864-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
10 Azzaroli F, Montagnani M, Porro A, Fiorillo D, Mazzella G. The future of dual therapy for hepatitis C virus. Future Virology 2014;9:905-12. [DOI: 10.2217/fvl.14.78] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
11 Stahmeyer JT, Rossol S, Krauth C. Outcomes, costs and cost-effectiveness of treating hepatitis C with direct acting antivirals. J Comp Eff Res 2015;4:267-77. [PMID: 25960028 DOI: 10.2217/cer.15.13] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
12 Chen GF, Wei L, Chen J, Duan ZP, Dou XG, Xie Q, Zhang WH, Lu LG, Fan JG, Cheng J. Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data. PLoS One. 2016;11:e0155934. [PMID: 27276081 DOI: 10.1371/journal.pone.0155934] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
13 Kamal SM, Kassim S, El Gohary E, Fouad A, Nabegh L, Hafez T, Bahnasy K, Hassan H, Ghoraba D. The accuracy and cost-effectiveness of hepatitis C core antigen assay in the monitoring of anti-viral therapy in patients with chronic hepatitis C genotype 4. Aliment Pharmacol Ther 2015;42:307-18. [PMID: 26018116 DOI: 10.1111/apt.13261] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
14 Pfeil AM, Reich O, Guerra IM, Cure S, Negro F, Müllhaupt B, Lavanchy D, Schwenkglenks M. Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C. PLoS One 2015;10:e0126984. [PMID: 25974722 DOI: 10.1371/journal.pone.0126984] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
15 Deuffic-Burban S, Yazdanpanah Y. Fair prices for new direct-acting antiviral agents (DAAs) to make treatment for all affordable. Gut 2015;64:1190-1. [PMID: 25567116 DOI: 10.1136/gutjnl-2014-308507] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
16 Fraser I, Burger J, Lubbe M, Dranitsaris G, Sonderup M, Stander T. Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa. Pharmacoeconomics 2016;34:403-17. [PMID: 26666639 DOI: 10.1007/s40273-015-0356-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
17 Elsisi GH, Aburawash A, Waked E. Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non-Cirrhotic Patients: A Societal Perspective. Value Health Reg Issues 2017;13:7-15. [PMID: 29073993 DOI: 10.1016/j.vhri.2017.03.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
18 Au TH, Destache CJ, Vivekanandan R. Hepatitis C therapy: Looking toward interferon-sparing regimens. Journal of the American Pharmacists Association 2015;55:e72-86. [DOI: 10.1331/japha.2015.15508] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Clément V, Raimond V. Was It Worth Introducing Health Economic Evaluation of Innovative Drugs in the French Regulatory Setting? The Case of New Hepatitis C Drugs. Value Health 2019;22:220-4. [PMID: 30711067 DOI: 10.1016/j.jval.2018.08.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Li X, Chan NS, Tam AW, Hung IFN, Chan EW. Budget impact and cost-effectiveness analyses of direct-acting antivirals for chronic hepatitis C virus infection in Hong Kong. Eur J Clin Microbiol Infect Dis. 2017;36:1801-1809. [PMID: 28516201 DOI: 10.1007/s10096-017-2995-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
21 Younossi ZM, Park H, Dieterich D, Saab S, Ahmed A, Gordon SC. Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: The quality-adjusted cost of care. Medicine (Baltimore) 2016;95:e5048. [PMID: 27741116 DOI: 10.1097/MD.0000000000005048] [Cited by in Crossref: 27] [Cited by in F6Publishing: 9] [Article Influence: 5.4] [Reference Citation Analysis]
22 Tasavon Gholamhoseini M, Sharafi H, Hl Borba H, Alavian SM, Sabermahani A, Hajarizadeh B. Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study. BMJ Open 2022;12:e058757. [PMID: 35676019 DOI: 10.1136/bmjopen-2021-058757] [Reference Citation Analysis]
23 Van Nuys K, Brookmeyer R, Chou JW, Dreyfus D, Dieterich D, Goldman DP. Broad Hepatitis C Treatment Scenarios Return Substantial Health Gains, But Capacity Is A Concern. Health Aff (Millwood) 2015;34:1666-74. [PMID: 26438742 DOI: 10.1377/hlthaff.2014.1193] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
24 Jafri SM, Gordon SC. The consequences of cirrhosis in America. Dig Dis Sci 2015;60:283-4. [PMID: 25399328 DOI: 10.1007/s10620-014-3425-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
25 Klebanoff MJ, Corey KE, Samur S, Choi JG, Kaplan LM, Chhatwal J, Hur C. Cost-effectiveness Analysis of Bariatric Surgery for Patients With Nonalcoholic Steatohepatitis Cirrhosis. JAMA Netw Open 2019;2:e190047. [PMID: 30794300 DOI: 10.1001/jamanetworkopen.2019.0047] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
26 Castro R, Crathorne L, Perazzo H, Silva J, Cooper C, Varley-Campbell J, Marinho DS, Haasova M, Veloso VG, Anderson R, Hyde C. Cost-effectiveness of diagnostic and therapeutic interventions for chronic hepatitis C: a systematic review of model-based analyses. BMC Med Res Methodol 2018;18:53. [PMID: 29895281 DOI: 10.1186/s12874-018-0515-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
27 Congly SE, Lee SS. Editorial: can we afford the new direct-acting antivirals for treatment of genotype 1 hepatitis C? Aliment Pharmacol Ther 2014;40:983-4. [PMID: 25229813 DOI: 10.1111/apt.12927] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
28 Mance D, Mance D, Vitezić D. Incremental cost-effectiveness pharmacoeconomic assessment of hepatitis C virus therapy: an approach for less wealthy members of the common market. Croat Med J 2016;57:582-90. [PMID: 28051283 DOI: 10.3325/cmj.2016.57.582] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
29 Chhatwal J, He T, Lopez-Olivo MA. Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals. Pharmacoeconomics 2016;34:551-67. [PMID: 26748919 DOI: 10.1007/s40273-015-0373-9] [Cited by in Crossref: 59] [Cited by in F6Publishing: 48] [Article Influence: 11.8] [Reference Citation Analysis]
30 Johnson SJ, Parisé H, Virabhak S, Filipovic I, Samp JC, Misurski D. Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection. J Med Econ 2016;19:983-94. [PMID: 27172133 DOI: 10.1080/13696998.2016.1189920] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
31 Younossi ZM, Jiang Y, Smith NJ, Stepanova M, Beckerman R. Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States. Hepatology 2015;61:1471-8. [PMID: 25706754 DOI: 10.1002/hep.27757] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.9] [Reference Citation Analysis]
32 Chhatwal J, He T, Hur C, Lopez-Olivo MA. Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving. Clin Gastroenterol Hepatol. 2017;15:827-837.e8. [PMID: 27650326 DOI: 10.1016/j.cgh.2016.09.015] [Cited by in Crossref: 63] [Cited by in F6Publishing: 51] [Article Influence: 10.5] [Reference Citation Analysis]
33 Pourhoseingholi MA, Ashtari S, Alavian SM. Sofosbuvir vs. Combination of Pegylated Interferon and Ribavirin; How Much Shall Pay for Iranian Patients? Hepat Mon 2014;14:e25540. [PMID: 25598793 DOI: 10.5812/hepatmon.25540] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
34 Mantovani LG, Cortesi PA, Strazzabosco M. Effective but costly: How to tackle difficult trade-offs in evaluating health improving technologies in liver diseases. Hepatology 2016;64:1331-42. [PMID: 26926906 DOI: 10.1002/hep.28527] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
35 Younossi ZM. The price of shortening anti-hepatitis C virus therapy: Is this truly cost saving? Clin Liver Dis (Hoboken) 2015;6:126-8. [PMID: 31041007 DOI: 10.1002/cld.514] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
36 Best MJ, Buller LT, Klika AK, Barsoum WK. Increase in perioperative complications following primary total hip and knee arthroplasty in patients with hepatitis C without cirrhosis. J Arthroplasty. 2015;30:663-668. [PMID: 25492245 DOI: 10.1016/j.arth.2014.11.013] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
37 Buti M, Domínguez-Hernández R, Oyagüez I, Casado MÁ. [Cost-effectiveness analysis of sofosbuvir, peginterferon and ribavirin in patients with chronic hepatitis C: Early treatment in the initial stage of fibrosis vs. delayed treatment in advanced fibrosis]. Gastroenterol Hepatol 2016;39:449-57. [PMID: 27084669 DOI: 10.1016/j.gastrohep.2016.03.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
38 Saab S, Younossi ZM. Editorial: can we afford the new direct-acting anti-virals for treatment of genotype 1 hepatitis C? Authors' reply. Aliment Pharmacol Ther 2014;40:984-5. [PMID: 25229814 DOI: 10.1111/apt.12939] [Reference Citation Analysis]
39 McElroy HJ, Roberts SK, Thompson AJ, Angus PW, McKenna SJ, Warren E, Musgrave S. Medical resource utilization and costs among Australian patients with genotype 1 chronic hepatitis C: results of a retrospective observational study. J Med Econ 2017;20:72-81. [PMID: 27552282 DOI: 10.1080/13696998.2016.1227827] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
40 Mattingly TJ 2nd, Pandit NS, Onukwugha E. Burden of Co-Infection: A Cost Analysis of Human Immunodeficiency Virus in a Commercially Insured Hepatitis C Virus Population. Infect Dis Ther 2019;8:219-28. [PMID: 30825134 DOI: 10.1007/s40121-019-0240-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
41 Gordon SC, Lamerato LE, Rupp LB, Holmberg SD, Moorman AC, Spradling PR, Teshale E, Xu F, Boscarino JA, Vijayadeva V, Schmidt MA, Oja-Tebbe N, Lu M. Prevalence of cirrhosis in hepatitis C patients in the Chronic Hepatitis Cohort Study (CHeCS): a retrospective and prospective observational study. Am J Gastroenterol 2015;110:1169-77; quiz 1178. [PMID: 26215529 DOI: 10.1038/ajg.2015.203] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
42 Faria R, Woods B, Griffin S, Palmer S, Sculpher M, Ryder SD. Prevention of progression to cirrhosis in hepatitis C with fibrosis: effectiveness and cost effectiveness of sequential therapy with new direct-acting anti-virals. Aliment Pharmacol Ther 2016;44:866-76. [DOI: 10.1111/apt.13775] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
43 Goudarzi Z, Poursamad A, Karimzadeh I, Jallaly N, Keshavarz K, Alavian SM. Cost-utility Analysis of Second-generation Direct-acting Antivirals for Hepatitis C. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon118646] [Reference Citation Analysis]
44 Puig-Junoy J, Pascual-Argente N, Puig-Codina L, Planellas L, Solozabal M. Cost-utility analysis of second-generation direct-acting antivirals for hepatitis C: a systematic review. Expert Rev Gastroenterol Hepatol 2018;12:1251-63. [PMID: 30791790 DOI: 10.1080/17474124.2018.1540929] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
45 Younossi ZM, Park H, Saab S, Ahmed A, Dieterich D, Gordon SC. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther. 2015;41:544-563. [PMID: 25619871 DOI: 10.1111/apt.13081] [Cited by in Crossref: 87] [Cited by in F6Publishing: 83] [Article Influence: 12.4] [Reference Citation Analysis]
46 Saab S, Parisé H, Virabhak S, Wang A, Marx SE, Sanchez Gonzalez Y, Misurski D, Johnson S. Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US. J Med Econ 2016;19:795-805. [PMID: 27063573 DOI: 10.1080/13696998.2016.1176030] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
47 Njei B, McCarty TR, Fortune BE, Lim JK. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis. Aliment Pharmacol Ther 2016;44:1090-101. [PMID: 27640785 DOI: 10.1111/apt.13798] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
48 Bickerstaff C. The cost-effectiveness of novel direct acting antiviral agent therapies for the treatment of chronic hepatitis C. Expert Rev Pharmacoecon Outcomes Res 2015;15:787-800. [PMID: 26289734 DOI: 10.1586/14737167.2015.1076337] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
49 Ji D, Chen GF, Wang C, Wang YD, Shao Q, Li B, Zhao J, You SL, Hu JH, Liu JL, Niu XX, Chen J, Lu L, Wu V, Lau G. Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients. Hepatol Int. 2016;10:789-798. [PMID: 27443347 DOI: 10.1007/s12072-016-9755-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
50 Sethi N, Tapper EB, Vong A, Sethi S, Rourke M, Afdhal NH. Direct costs of first-generation protease inhibitors for the treatment of genotype 1 chronic hepatitis C viral infection. J Viral Hepat 2015;22:974-6. [PMID: 26010946 DOI: 10.1111/jvh.12421] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
51 Gordon S, Lee J, Smith N, Dieterich D. Cost-effectiveness of pan-genotypic direct-acting antiviral regimens for treatment of chronic Hepatitis C in the United States. Expert Rev Pharmacoecon Outcomes Res 2020;20:251-7. [PMID: 31204882 DOI: 10.1080/14737167.2019.1629291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]